ReviewClinical interventions in aging2009
Emerging treatments for postmenopausal osteoporosis - focus on denosumab.
Review in Clinical interventions in aging, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- Inflammatory responses improve with milk ribonuclease-enriched lactoferrin supplementation in postmenopausal women.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2010Trial
- Plasma osteoprotegerin is associated with testosterone levels but unaffected by pioglitazone treatment in patients with polycystic ovary syndrome.Journal of endocrinological investigationTrial
- Osteoprotegerin and receptor activator of NF-kappaB ligand as biomarkers for bone resorption-related disorders.World journal of experimental medicine · 2026Review
- Medication-Related Osteonecrosis of the Jaws (MRONJ) in Children and Young Patients-A Systematic Review.Journal of clinical medicine · 2023Review
- A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients.Scientific reports · 2022Article
- Dental care for patients taking antiresorptive drugs: a literature review.Restorative dentistry & endodontics · 2019Review
- Design of a RANK-Mimetic Peptide Inhibitor of Osteoclastogenesis with Enhanced RANKL-Binding Affinity.Molecules and cells · 2016Article
- OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2015Article
- The role of "bone immunological niche" for a new pathogenetic paradigm of osteoporosis.Analytical cellular pathology (Amsterdam) · 2015Review
- RANK-Ligand inhibitor associated osteonecrosis of the jaw.GMS Interdisciplinary plastic and reconstructive surgery DGPW · 2013Article
- Transient muscle paralysis degrades bone via rapid osteoclastogenesis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2012Article
- Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion.Therapeutic advances in medical oncology · 2011Article
- Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss.Clinical interventions in aging · 2010Review
- Novel functions for NFκB: inhibition of bone formation.Nature reviews. Rheumatology · 2010Review
- Osteonecrosis of the jaw in a patient on Denosumab.Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons · 2010Article
- Osteoclast-targeting small molecules for the treatment of neoplastic bone metastases.Cancer science · 2009Review
- Progress in osteoporosis and fracture prevention: focus on postmenopausal women.Arthritis research & therapy · 2009Review
- Breast Cancer: Rank Ligand Inhibition.Breast care (Basel, Switzerland)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pathway of the receptor activator of the nuclear factor kappaB ligand (RANKL), RANK and osteoprotegerin (OPG) plays a central role in coupling bone formation and resorption during normal bone turnover and in a wide spectrum of diseases characterized by disturbed bone remodeling, increased bone resorption and bone destruction (osteoporosis, Paget's disease of bone, rheumatoid arthritis [RA], metastatic bone disease). Clinical trials indicate that denosumab, a RANKL-specific recombinant humanized monoclonal antibody, is effective in suppressing bone resorption, resulting in increase in bone mineral density (BMD) in post-menopausal women with low BMD, and has the potential to prevent progression of erosions in RA and of skeletal-related events in metastatic bone disease. The effects on fracture reduction in postmenopausal osteoporosis are awaited from the recently finished FREEDOM study. In clinical trials with denosumab, overall adverse events were similar to placebo or comparators, indicating a favorable safety profile in these diseases, which until now have been available up to 4 years, but data on long-term safety will be needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.